c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: Prognostic value

Breast Cancer Research and Treatment

Volumn 51, Issue 2, 1998, Pages 109-119

  Molina, Rafael ^a   Jo, Judith ^a   Filella, Xavier ^a   Zanon, Gabriel ^a   Pahisa, Jaume ^a   Muñoz, Montserrat ^a   Farrus, Blanca ^a   Latre, Maria Luz ^a   Escriche, Carmen ^a   Estape, Jordi ^a   Ballesta, Antonio M ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Breast cancer; c erbB 2; CA 15.3; CEA; Prognosis; Tumor markers; Tumor associated antigens

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; ONCOPROTEIN; STEROID RECEPTOR; TUMOR MARKER;

ADVANCED CANCER; ARTICLE; BLOOD LEVEL; BREAST CANCER; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; HUMAN; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; ONCOGENE C ERB; PRIORITY JOURNAL; PROGNOSIS; TISSUE LEVEL; TUMOR VOLUME;

BREAST NEOPLASMS; CA-15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MULTIVARIATE ANALYSIS; PROGNOSIS; RECEPTOR, ERBB-2; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 7844249246     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005734429304     Document Type: Article

References (28)

1. Hilkens J, Kroezen V, Bonfrer JMG, Bruning PF, Hilgers J, van Eijkeren J: A radioimmunoassay for a new antigen (Mam-6) present in the sera of patients with metastasized carcinomas. In: Peeters H (ed) Protides of the Biological Fluids. Pergamon Press, Oxford, 1985, pp 651-653
2. Kufe D, Inghirami G, Abe M, Hayes D, Justi-Wheeler H, Schlom J: Differential reactivity of a novel monoclonal antibody (DF-3) with human malignant versus benign breast tumors. Hybridoma 3: 223-232, 1984
3. Stahli C, Takacs B, Miggiano V, Staehelin T, Carman H: Monoclonal antibodies against antigens on breast cancer cells. Experientia 41: 1377-1381, 1985
4. Colomer R, Ruibal A, Salvador L: Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer 64: 1674-1681, 1989
5. Molina R, Ballesta AM: Evaluation of several tumor markers (MCA, CA 15.3, BCM and CA 549) in tissue and serum of patients with breast cancer. In: Ceriani RL (ed) Breast Epithelial Antigens. Molecular Biology to Clinical Applications. Plenum Press, New York 1991, pp 161-168
6. Molina R, Zanon G, Filella X, Moreno F, Jo J, Daniels M, Latre ML, Gimenez N, Pahisa J, Velasco M, Ballesta AM: Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat 36: 41-48, 1995
7. Coussens L, Yang-Feng TL, Liao YC et al.: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with the neu oncogene. Science 230: 1130-1139, 1985
8. Molina R, Ciocca R, Tandon AK, Allred DC, Clark GC, Chamness GC, Gullick WJ, McGuire WL: Expression of HER-2/neu oncoprotein in human breast cancer. A comparison of immunohistochemical and western blot techniques. Anticancer Res 12: 1965-1972, 1992
9. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Ress MF: Studies of the HER-2 neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989
10. Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL: HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 7: 1120-1128, 1989
11. Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC, Abeloff MD, McGuire WL: Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Human Pathol 23: 974-979, 1992
12. Berger MS, Locher GW, Saurer S et al.: Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 48: 1238-1243, 1988
13. Marx D, Schauer A, Reiche Ch et al.: c-erbB-2 expression in correlation to other biological parameters of breast cancer. J Cancer Res Clin Oncol 116: 15-20, 1990
14. Molina R, Filella X, Segui MA, Climent MA, Perez-Picañol E, Alonso C, Jo J, Ojeda B, Tandon AK, Ballesta AM: Oncogenic proteins and prognostic correlations in breast cancer. In vivo 7: 585-590, 1993
15. Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff MD, McGuire WL: HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 4: 599-605, 1992
16. Zabrecky JR, Lam T, McKenzie SJ, Carney W: The extracellular domain of p185 neu is released from the surface of human breast carcinoma cell, SK-BR-3. J Biol Chem 266: 1716-1720, 1991
17. Pupa SM, Menard S, Morelli D, Pozzi B, De Palo G, Colnaghi MI: The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene 8: 2917-2923, 1993
18. MeKenzie SJ, De Sombre KA, Bast BS, Hollis DR, Whitaker RS, Berchuck A, Boyer CM, Bast RC: Serum levels of HER-2/neu (C-erbB-2) correlate with overexpression of p184 neu in human ovarian cancer. Cancer 71: 3942-3946, 1993
19. Narita T, Funahashi H, Satoh Y, Takagi H: C-erbB-2 in the sera of breast cancer patients. Breast Cancer Res Treat 24: 97-102, 1992
20. International Union Against Cancer (UICC): TNM classification of malignant tumours. In: Hermanek P, Soben LH (eds) 4 ed Springer Verlag, Berlin, 1987
21. Molina R, Jo J, Filella X, Bruix J, Castells A, Hague M, Ballesta AM: Serum levels of c-erbB-2 (HER-2/neu) in patients with malignant and non-malignant diseases. Tumour Biology 18: 188-196, 1997
22. Zhou DJ, Ahauja H, Cline MJ: Proto-oncogene abnormalities in human breast cancer: c-erbB-2 amplification does not correlate with recurrence of disease. Oncogene 4: 105-108, 1989
23. Molina R, Filella X, Torres MD, Ballesta AM, Mengual P, Cases A, Balague A: SCC antigen measured in malignant and nonmalignant diseases. Clin Chem 36: 251-254, 1990
24. Molina R, Filella X, Bruix J, Mengual P, Bosch J, Calvet X, Jo J, Ballesta AM: Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases. Clin Chem 37: 1379-1383, 1991
25. Cases A, Filella X, Molina R, Ballesta AM, Lopez-Revert J, Revert L: Tumor markers in chronic renal failure and hemodialysis patients. Nephron 37: 1379-1383, 1991
26. Ritts RE Jr, Del Villano BC, Go VLW, Heberman RB, Klug TL, Zurawski VR Jr: Initial clinical evaluation of an immunoradiometric assay for CA 19.9 using the NCI serum bank. Int J Cancer 33: 339-345, 1984
27. Leitzel K, Teramoto Y, Konrad K, Chinchilli VM, Volas G, Grossberg H, Harvey H, Demers L, Lipton A: Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13: 1129-1135, 1995
28. Molina R, Jo J, Zanon G, Filella X, Farrus M, Muñoz M, Latre ML, Pahisa J, Velasco M, Fernandez P, Estapé J, Ballesta AM: Utility of c-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3. Br J Cancer 74: 1126-1131, 1996